Receive our newsletter – data, insights and analysis delivered to you
June 1, 2009

Immunomedics’ Targeted Radiation Therapy Combo Trials Positive

Immunomedics has reported a 30% objective response rate after treating ten evaluable patients with inoperable advanced pancreatic cancer with the company's new targeted radiation therapy in combination with gemcitabine. The interim results from the ongoing Phase II dose-escalation study w

By cms admin

Immunomedics has reported a 30% objective response rate after treating ten evaluable patients with inoperable advanced pancreatic cancer with the company’s new targeted radiation therapy in combination with gemcitabine.

The interim results from the ongoing Phase II dose-escalation study were presented at the 2009 Annual Meeting of American Society of Clinical Oncology.

Immunomedics president and CEO Cynthia Sullivan said that the test data corroborated the notion that targeted radiation therapy was well suited for solid cancers.

“In light of the fact that there aren’t many viable treatment options for patients with advanced pancreatic cancer, we believe clivatuzumab tetraxetan labelled with yttrium-90 is in a good position to become the first radioimmunotherapeutic agent for pancreatic cancer therapy,” said Sullivan.

“We currently intend to develop it through commercialisation on our own.”

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU